$INTS

INTENSITY THERAPEUTICS, INC. (INTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. intensity-20260616 0001567264 FALSE 0001567264 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event repor

Intensity Therapeutics (INTS) has increased its at-the-market (ATM) offering capacity to $60.0 million to improve its financial flexibility. This allows the company to issue common stock, though it is not obligated to sell shares, maintaining discretion based on market conditions and strategy. The ATM program is conducted with H.C. Wainwright & Co. as the sales agent, as detailed in an SEC filing from March 23, 2026.

Intensity Therapeutics, Inc. has increased its at-the-market (ATM) stock offering program capacity to $60.0 million. This expansion provides the company with greater financial flexibility to raise equity capital through the sale of common shares via H.C. Wainwright & Co. LLC, although the company is not obligated to issue any shares. The decision to utilize the ATM program will depend on market conditions and the company's strategic priorities.

Intensity Therapeutics (NASDAQ:INTS) has increased its At-The-Market (ATM) offering capacity to $60 million, effective March 23, 2026, by supplementing its July 11, 2024 sales agreement. The company has already sold 1,297,655 shares under the previous agreement, totaling $12,029,360 in gross sales. H.C. Wainwright & Co., LLC continues to act as the agent for the ATM offering, with all other terms of the agreement remaining unchanged.

Intensity Therapeutics Inc. ( NASDAQ:INTS ) shares are trending on Friday. Check out the current price of INTS stock here.

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded up 0.03% to 47,644.08 while the NASDAQ fell 1.13% to 23,687.37. The S&P 500 also fell, dropping, 0.63% to 6,847.40.

SHELTON, Conn., Aug. 12, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc.

Intensity Therapeutics ( NASDAQ:INTS ) , a clinical-stage biotechnology company focused on direct tumor-targeted treatments, released its second quarter 2025 earnings on August 7, 2025. The quarter's headline news is a significant reduction in operating expenses, achieved while maintaining ...

Intensity Therapeutics shares are trading lower by 34.9% during Friday's session. The company announced the pricing of a public offering expected to raise approximately $2.35 million. Don't face extreme market conditions unprepared.

Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.